Aussie Scientists ID Gene That Blocks Main Hepatitis C Drugs In Many
This article was originally published in PharmAsia News
Executive Summary
Australian researchers say they have identified the gene responsible for the lack of the ability of half of Australians infected with hepatitis C to respond to conventional treatment. The Westmead Millenium Institute scientists said the interferon lambda gene has the ability to block the effectiveness of drugs used to treat the chronic infection of liver diseases. About 200,000 Australians have hepatitis C, half of whom fail to respond to the usual treatments. (Click here for more
You may also be interested in...
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.